The FDA announced on July 1, 2013, that Fresenius Kabi USA, LLC is recalling Benztropine Mesylate Injection due to the presence of particulate matter. The agency classified the recall as Class II.
How to tell if you have it
- Brand: Fresenius Kabi
- Product: Benztropine Mesylate Injection, USP, 2 mg/2 mL (1 mg/1 mL), 2 mL Single Dose Vial
- NDC 63323-970-02, Lot 111412, Exp: 11/2014
- NDC 14789-300-02, Lots 030712 (Exp: 03/2014), 071212 (Exp: 07/2014), 090512 (Exp: 09/2014)
- Units affected: 65,110 vials
The hazard
The recall addresses the presence of particulate matter characterized as thin colorless flakes consistent with glass delamination. This hazard was observed in reserve sample vials.
Context
GovInfoNow's records show Fresenius Kabi USA, LLC has 65 other recalls on record since 2012-09-27. Other recent recalls of similar products include Fresenius Kabi Tyenne Injection Recall (2026-08-10), Fresen: Morphine Syringes May Have Wrong Labeling (2026-08-04), and Fresenius Kabi Lidocaine HCl Injection Recall (2026-07-16). Other recent recalls of similar products include Liebel-Flarsheim Optiray Imaging Bulk Package-350 Recall (2026-07-31), Sun Pharmaceutical DOXOrubin Liposome Injection Recall (2026-05-12), and Mallinckrodt Acthar Gel 5mL Vial Recall (2026-08-06).